Seven of 10 infants had near-total or total clearance after two months with once-weekly treatments

Less heterogeneity in sensitivity, specificity, accuracy seen when clinicians worked in unison with artificial intelligence

Zevtera approved for S. aureus bloodstream infections, acute bacterial skin/skin structure infections, and bacterial pneumonia

Improvement seen in all signs of photoaging as early as week 4 and through 12 weeks, with no major irritation

Five themes affect long-term prescribing, including perceived lack of evidence to justify change, discomfort discussing contraception

Greater adherence to annual dermatology visits leads to reduced melanoma-specific mortality

Oral minoxidil can be an option for patients who would rather take an oral therapy or cannot tolerate topical treatment

Final model composed of six prognostic factors showed good prediction in development cohort and external validation

Significant improvement seen in IGA response and PSSI 90, with no serious treatment-related adverse events

Women have increased risk for thyroid, renal, lung cancers; men have highest risk for melanoma, bladder, prostate cancers

Findings seen in patients with primary cutaneous melanoma undergoing SLN biopsy and those who progressed to unresectable stage

Researchers find all skin surface temperature measures differ significantly between cellulitis and pseudocellulitis

Increases seen in social media use and cosmetic consultations during the COVID-19 pandemic

Most patients report an increase in trust in quality of medical care if they were asked for consent to use medical image

No significant reduction seen in incidence rates of actinic keratoses; no changes observed in anxiety, depression surveys

No safety concerns observed during 36 weeks of treatment with delgocitinib cream 20 mg/g

Proportion of patients achieving Severity of Alopecia Tool score ≤20 increased through 68 weeks of open-label extension

Patients achieving SALT score ≤20 increased from 44.5 to 75.8 percent at week 52 to week 76

Among patients with atopic dermatitis and self-reported race other than White, 68.3 percent achieved EASI 75 at week 16

After four years of bimekizumab treatment, more than six in 10 patients achieved and maintained complete skin clearance